TD Cowen maintains MSD's “holding” rating, arguing that the success of the cancer vaccine did not completely eliminate uncertainty. Although pharmaceutical giant MSD announced the success of its cancer vaccine in large-scale trials this Wednesday, TD Cowen maintained its “hold” rating on the stock. TD Cowen analyst Steve Scala stated in a report to clients on Thursday: “Given the strong previous phase II clinical data, this success is no surprise. The positive results have indeed proven it, but the breadth of its potential applications is still unknown.” Currently, TD Cowen's price target for MSD is $137, while the stock closed at $152.20 on Wednesday.

Zhitongcaijing · 1d ago
TD Cowen maintains MSD's “holding” rating, arguing that the success of the cancer vaccine did not completely eliminate uncertainty. Although pharmaceutical giant MSD announced the success of its cancer vaccine in large-scale trials this Wednesday, TD Cowen maintained its “hold” rating on the stock. TD Cowen analyst Steve Scala stated in a report to clients on Thursday: “Given the strong previous phase II clinical data, this success is no surprise. The positive results have indeed proven it, but the breadth of its potential applications is still unknown.” Currently, TD Cowen's price target for MSD is $137, while the stock closed at $152.20 on Wednesday.